Send to

Choose Destination
Clin Hemorheol Microcirc. 2019 Jun 3. doi: 10.3233/CH-199103. [Epub ahead of print]

Adjuvant drug-assisted bone healing: Part II - Modulation of angiogenesis.

Author information

Department of Radiopharmaceutical and Chemical Biology, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
University Center of Orthopaedics and Traumatology (OUC), University Hospital Carl Gustav Carus, Dresden, Germany.
Center for Translational Bone, Joint and Soft Tissue Research, University Hospital Carl Gustav Carus and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.
Center for Regenerative Therapies Dresden (CRTD), Tatzberg 4, Dresden, Germany.
Technische Universität Dresden, School of Science, Faculty of Chemistry and Food Chemistry, Dresden, Germany.


 The treatment of critical-size bone defects following complicated fractures, infections or tumor resections is a major challenge. The same applies to fractures in patients with impaired bone healing due to systemic inflammatory and metabolic diseases. Despite considerable progress in development and establishment of new surgical techniques, design of bone graft substitutes and imaging techniques, these scenarios still represent unresolved clinical problems. However, development of new active substances gives cause for hope. This work discusses therapeutic approaches that influence angiogenesis or hypoxic situations in healing bone and surrounding tissue. In particular, literature on sphingosine-1-phosphate receptor modulators and nitric oxide (NO•) donors, including bi-functional (hybrid) compounds like NO•-releasing cyclooxygenase-2 inhibitors, was critically reviewed with regard to their local and systemic mode of action.


Critical-size bone defects; neovascularization; nitric oxide donors; signaling; small molecules; sphingosine-1-phosphate receptor


Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center